Compare ANPA & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ANPA | TECX |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.0M | 359.0M |
| IPO Year | 2025 | 2018 |
| Metric | ANPA | TECX |
|---|---|---|
| Price | $22.50 | $19.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $81.20 |
| AVG Volume (30 Days) | 15.7K | ★ 328.2K |
| Earning Date | 09-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $5,832,684.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $390.11 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.80 | $13.70 |
| 52 Week High | $54.75 | $61.07 |
| Indicator | ANPA | TECX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 52.30 |
| Support Level | N/A | $18.60 |
| Resistance Level | N/A | $21.50 |
| Average True Range (ATR) | 0.00 | 1.65 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 0.00 | 47.69 |
Rich Sparkle Holdings Ltd is financial printing and corporate services provider which engaged in designing and printing financial print materials in Hong Kong. It service portfolio covers a myriad of deliverables, mainly including listing documents, financial reports, fund documents, circulars and announcements. The company's core business includes (i) financial printing services such as printing, typesetting and translation, (ii) advisory services including Environmental, Social and Governance Report and (iii) other services. Key revenue is generated from Financial printing services.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.